within Pharmacolibrary.Drugs.ATC.R;

model R06AX27
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.00015333333333333334,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.049,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.022166666666666668,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AX27</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Desloratadine is a non-sedating second-generation antihistamine used to treat symptoms associated with allergic rhinitis and chronic idiopathic urticaria. It is the active metabolite of loratadine and is widely approved and used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported following single oral administration of 5 mg desloratadine in healthy adult volunteers.</p><h4>References</h4><ol><li><p>McClellan, K, &amp; Jarvis, B (2001). Desloratadine. <i>Drugs</i> 61(6) 789–797. DOI:<a href=\"https://doi.org/10.2165/00003495-200161060-00007\">10.2165/00003495-200161060-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11398910/\">https://pubmed.ncbi.nlm.nih.gov/11398910</a></p></li><li><p>Molimard, M, et al., &amp; Benedetti, MS (2004). Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. <i>Fundamental &amp; clinical pharmacology</i> 18(4) 399–411. DOI:<a href=\"https://doi.org/10.1111/j.1472-8206.2004.00254.x\">10.1111/j.1472-8206.2004.00254.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15312146/\">https://pubmed.ncbi.nlm.nih.gov/15312146</a></p></li><li><p>Prenner, B, et al., &amp; Lutsky, B (2006). Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. <i>Expert opinion on drug safety</i> 5(2) 211–223. DOI:<a href=\"https://doi.org/10.1517/14740338.5.2.211\">10.1517/14740338.5.2.211</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16503743/\">https://pubmed.ncbi.nlm.nih.gov/16503743</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AX27;
